ARF controls vascular regression during eye development
ARF controls vascular regression during eye development
批准号:
7281190
负责人:
STEPHEN X SKAPEK
金额:
$1.52万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2008-07-31
关键词:
AddressAgeAngiogenic FactorAngiogenic SwitchAppendixAutomobile DrivingBlindnessBlood VesselsCancer BiologyCataractCellsClinicalCultured CellsDevelopmentDiseaseDisease regressionDysplasiaEmbryoEquilibriumEtiologyEyeEye AbnormalitiesEye DevelopmentEye diseasesFutureGeneticGenetically Engineered MouseGoalsHumanHyperplasiaIn Situ HybridizationIn VitroKnowledgeLacZ GenesLeadLifeMalignant NeoplasmsMediator of activation proteinModelingMolecularMouse StrainsMusNumbersNutrientPathogenesisPathologicPathologic ProcessesPatternPlayProtein p53ProteinsRegulationReporterReportingResearch PersonnelRetinal DetachmentRoleStreamTP53 geneTherapeuticTimeTissuesTumor Suppressor GenesTumor Suppressor ProteinsVascular SystemWeekangiogenesisbaseblocking factorhuman diseasein vivoinsightlenspostnatalpreventprogramsresearch studytumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The major goal of this proposal is to determine how Arf, a potent tumor suppressor, plays an essential role during eye development to prevent a severe developmental eye disease.
During mammalian eye development, the hyaloid vascular system (HVS) supplies nutrients to the developing eye and then completely involutes. Failed HVS regression is an integral component of a human eye disease known as persistent hyperplastic primary vitreous (PHPV), characterized by retrolental fibrovascular tissue in the vitreous, lens degeneration with cataract formation, and retinal detachment and dysplasia. Molecular mechanisms regulating HVS regression and the etiology of PHPV are largely unknown. However, occasional clinical reports of familial PHPV suggest that it may have a genetic basis.
Recently, we have made the unexpected discovery that the Arf tumor suppressor gene is essential for the normal development of the mouse eye. Specifically, the HVS fails to involute and eye abnormalities that closely mimic PHPV develop in the first weeks of life in Arf-deficient mice. The pattern and timing of Arf expression during mouse eye development suggest that it may play a primary role in promoting HVS regression. The function of the Arf gene product during eye development appears to be independent of its known "down-stream" genetic target, p53. These findings provide the first evidence that Arf regulates eye development and that Arf may be an essential mediator of HVS regression to prevent a PHPV-like eye disease.
We will couple in vivo studies of Arf-/- mice and new genetically-engineered mouse strains with in vitro studies to elucidate the mechanisms by which Arf promotes normal HVS regression in the developing eye. Specifically, our experiments will (1) identify and characterize the Arf-expressing cells in the embryonic and postnatal eye; (2) determine whether it acts in a cell-autonomous manner to promote normal eye development; and (3) elucidate the cellular and molecular effects of Arf that are required for vitreous maturation and HVS involution. The successful completion of our experiments will provide new insight into cellular and molecular mechanisms driving HVS regression in the eye. This should augment our knowledge of Arf function and begin to clarify the molecular pathogenesis for PHPV and potentially other vascular eye diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma
-
批准号:10642101
-
项目类别:
-
资助金额:$23.0万
-
财政年份:2023
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Identifying neuroblastoma drivers and bringing them to the clinic
-
批准号:10197505
-
项目类别:
-
资助金额:$43.74万
-
财政年份:2021
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors
-
批准号:8932163
-
项目类别:
-
资助金额:$48.55万
-
财政年份:2015
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Development and Cancer Scientific Program
-
批准号:10260731
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2010
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Development and Cancer Program
-
批准号:10477964
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2010
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Development and Cancer Program
-
批准号:10170614
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2010
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf 2-2 controls p19Arf during eye development
-
批准号:7994803
-
项目类别:
-
资助金额:$33.7万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf 2-2 controls p19Arf during eye development
-
批准号:7769253
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Translation of Predictive Cancer Biomarkers into Clinical Practice
-
批准号:7855461
-
项目类别:
-
资助金额:$155.32万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Physician Scientist Oncology Training Program
-
批准号:8931904
-
项目类别:
-
资助金额:$22.87万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Translation of Predictive Cancer Biomarkers into Clinical Practice
-
批准号:7943955
-
项目类别:
-
资助金额:$130.89万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf 2-2 controls p19Arf during eye development
-
批准号:8391354
-
项目类别:
-
资助金额:$34.26万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf Beta 2 controls p19Arf During Eye Development
-
批准号:9247201
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf Beta 2 controls p19Arf During Eye Development
-
批准号:9039602
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Tgf Beta 2 controls p19Arf During Eye Development
-
批准号:8696467
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
Physician Scientist Oncology Training Program
-
批准号:9331424
-
项目类别:
-
资助金额:$24.53万
-
财政年份:2009
-
负责人:STEPHEN X SKAPEK
-
依托单位:
ARF Controls Vascular Regression During Eye Development
-
批准号:8336897
-
项目类别:
-
资助金额:$38.16万
-
财政年份:2003
-
负责人:STEPHEN X SKAPEK
-
依托单位:
ARF controls vascular regression during eye development
-
批准号:6779923
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:STEPHEN X SKAPEK
-
依托单位:
ARF controls vascular regression during eye development
-
批准号:7112255
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2003
-
负责人:STEPHEN X SKAPEK
-
依托单位:
ARF Controls Vascular Regression During Eye Development
-
批准号:7898745
-
项目类别:
-
资助金额:$38.12万
-
财政年份:2003
-
负责人:STEPHEN X SKAPEK
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: